Moreover, empagliflozin has been indicated to reduce oxidative stress-induced damage (by activation of the Akt/GSK-3 signaling pathway) and target inflammation and fibrosis by the downregulation of TGF-ß1 in a model of diabetic nephropathy [23]. Here, AKT1 is linked to diabetic kidney disease.